StockNews.com Lowers Jaguar Health (NASDAQ:JAGX) to Sell

StockNews.com downgraded shares of Jaguar Health (NASDAQ:JAGX) from a hold rating to a sell rating in a research report sent to investors on Monday.

Jaguar Health Stock Performance

Jaguar Health stock opened at $3.62 on Monday. The business has a fifty day moving average of $8.77 and a two-hundred day moving average of $7.20. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.39 and a current ratio of 1.89. Jaguar Health has a twelve month low of $3.07 and a twelve month high of $41.76.

Jaguar Health (NASDAQ:JAGX) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($3.60) earnings per share for the quarter. The company had revenue of $2.35 million for the quarter. Jaguar Health had a negative return on equity of 642.15% and a negative net margin of 377.95%. On average, research analysts predict that Jaguar Health will post -5.42 EPS for the current fiscal year.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.